medRxivGenetic & Genomic MedicinePreprint
Resolution of SLC6A1 variable expressivity in a multi-generational family using deep clinical phenotyping and Drosophila models
Kristy L. Jay, Nikhita GogateiD, Kimberly M. EzelliD, Jonathan C. AndrewsiD, Sharayu V. JangamiD, Paige I. HalliD, Hongling Pan, Kelvin Pham, Ryan J. GermaniD, Vanessa Gomez, Emily R. Jellinek, Eric A. StorchiD, Undiagnosed Diseases Network, Shinya YamamotoiD, Oguz KancaiD, Hugo Jozef BelleniD, Herman A. DierickiD, Joy D. CoganiD, John A. Phillips, Rizwan HamidiD, Thomas A. CassiniiD, Lynette C. Rives, Jennifer Ellen PoseyiD, Michael F. WangleriD
Abstract
PurposeVariants in SLC6A1 result in a rare neurodevelopmental disorder characterized by a variable clinical presentation of symptoms including developmental delay, epilepsy, motor dysfunction, and autism spectrum disorder. SLC6A1 haploinsufficiency has been confirmed as the predominant pathway of SLC6A1-related neurodevelopmental disorders (NDDs), however, the molecular mechanism underlying the variable clinical presentation remains unclear. MethodsHere, through work of the Undiagnosed Diseases Network, we identify an undiagnosed individual with an inherited p.(A334S) variant of uncertain significance. To resolve this case and better understand the variable expressivity with SLC6A1, we assess the phenotypes of the proband with a cohort of cases diagnosed with SLC6A1-related NDDs. We then create an allelic series in the Drosophila melanogaster to functionally characterize case variants. ResultsWe identify significant clinical overlap between the unsolved case and confirmed cases of SLC6A1-related NDDs and find a mild to severe clinical presentation associated with missense variants. We confirm phenotypes in flies expressing SLC6A1 variants consistent with a partial loss-of-function mechanism. ConclusionWe conclude that the p.(A334S) variant is a hypomorphic allele and begin to elucidate the underlying variability in SLC6A1-related NDDs. These insights will inform clinical diagnosis, prognosis, treatment and inform therapeutic design for those living with SLC6A1- related NDDs.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Haploinsufficiency underlies the neurodevelopmental consequences of SLC6A1/GAT-1 variants
Dina Buitrago Silva, Marena I. Trinidad, … Arthur Wüster·medRxiv·Mar 9, 2022
- Molecular genetics of GLUT1DS Italian pediatric cohort: 10 novel related-disease variants and structural analysis
Alessia Mauri, Alessandra Duse, … Cristina Cereda·International Journal of Molecular SciencesPeer-reviewed·Nov 4, 2022
- Characterization of SETD1A haploinsufficiency in humans and Drosophila defines a novel neurodevelopmental syndrome.
Joost Kummeling, Diante E. Stremmelaar, … Tjitske Kleefstra·Molecular PsychiatryPeer-reviewed·Apr 28, 2020
- Delineating the molecular and phenotypic spectrum of the SETD1B-related syndrome
Marjolein J.A. Weerts, Kristina Lanko, … Tahsin Stefan Barakat·Genetics in MedicinePeer-reviewed·Aug 3, 2021
- Accumulation of Extracellular GABA, Impaired GABAergic Neurotransmission and 4-Phenylbutyrate Rescue in Mice of SLC6A1 Variant-Mediated Disorders
Kirill A. Zavalin, Karishma Randhave, … Jing‐Qiong Kang·bioRxiv·Jan 21, 2026
- A synonymous SLC2A1 variant causes familial epilepsy and paroxysmal exercise-induced dyskinesia by creating aberrant mosaic splicing patterns
Adam T. Higgins, Fiona Wang, … Seo‐Kyung Chung·medRxiv·Apr 5, 2025